Search research articles
Contact Us
Filters
Showing results (101-110 of 107) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 107 results.
Journal of Viral Hepatitis
|
December 16, 2016
Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older
F Conti, S Brillanti, F Buonfiglioli, et al.
Gut
|
November 13, 2002
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data
C Cammà, S Bruno, F Schepis, et al.
Journal of Viral Hepatitis
|
August 7, 2012
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3
S Pianko, S Zeuzem, W-L Chuang, et al.
Alimentary Pharmacology & Therapeutics
|
May 4, 2018
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma
M Persico, A Aglitti, A Aghemo, et al.
Journal of Viral Hepatitis
|
March 16, 2013
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin
G R Foster, S Zeuzem, S Pianko, et al.
Alimentary Pharmacology & Therapeutics
|
June 14, 2008
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation
F Lodato, S Berardi, A Gramenzi, et al.
Journal of Viral Hepatitis
|
April 4, 2017
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis
R Vukotic, F Conti, S Fagiuoli, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 107) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 107 results.
Journal of Viral Hepatitis
|
December 16, 2016
Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older
F Conti, S Brillanti, F Buonfiglioli, et al.
Gut
|
November 13, 2002
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data
C Cammà, S Bruno, F Schepis, et al.
Journal of Viral Hepatitis
|
August 7, 2012
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3
S Pianko, S Zeuzem, W-L Chuang, et al.
Alimentary Pharmacology & Therapeutics
|
May 4, 2018
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma
M Persico, A Aglitti, A Aghemo, et al.
Journal of Viral Hepatitis
|
March 16, 2013
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin
G R Foster, S Zeuzem, S Pianko, et al.
Alimentary Pharmacology & Therapeutics
|
June 14, 2008
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation
F Lodato, S Berardi, A Gramenzi, et al.
Journal of Viral Hepatitis
|
April 4, 2017
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis
R Vukotic, F Conti, S Fagiuoli, et al.
Page
of 11